4 Analysts Have This to Say About Soleno Therapeutics
Portfolio Pulse from Benzinga Insights
Soleno Therapeutics (NASDAQ:SLNO) has received updated analyst ratings in the last quarter, with an average price target of $27.00, a significant increase from the previous target of $13.50. The ratings include 1 bullish and 3 somewhat bullish ratings, with no indifferent, somewhat bearish, or bearish ratings. The high price target is $40.00 and the low is $14.00. Analysts use various data sources to provide these ratings, which are opinions and can vary in accuracy.
November 21, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Soleno Therapeutics has received positive analyst ratings with an average 12-month price target of $27.00, reflecting a 100% increase from the previous target. The ratings suggest a positive outlook for the stock.
The unanimous somewhat bullish to bullish ratings from analysts, combined with a significant increase in the average price target, suggest a strong positive sentiment towards Soleno Therapeutics. This could lead to increased investor confidence and a potential short-term rise in the stock price. However, as analyst ratings are opinions, the actual market performance will depend on broader market conditions and company performance.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100